Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2019-05-09 AGM Information
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec SE: Bekanntmachung der Einberufung zur Hauptversammlung am 19.06.2019 in Hamburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 100% confidence The document is explicitly titled 'Bekanntmachung der Einberufung zur Hauptversammlung am 19.06.2019' (Announcement of the Convocation to the Annual General Meeting on June 19, 2019). It details the agenda (Tagesordnung) for the 'ordentlichen Hauptversammlung 2019' (Ordinary Annual General Meeting 2019), including items like the presentation of financial statements, discharge of board members, auditor appointment, and election of the Supervisory Board members. This content directly corresponds to the materials presented or announced for an Annual General Meeting. Therefore, the classification is AGM-R.
2019-05-09 German
EVOTEC SE TO REPORT FIRST QUARTER 2019 RESULTS ON 14 MAY 2019
Report Publication Announcement Classification · 99% confidence The document is a news release dated May 7, 2019, announcing that EVOTEC SE will report its financial results for the first quarter of 2019 on May 14, 2019. It explicitly states the date and time for the conference call to discuss these results. This is a forward-looking announcement about the release of financial results, not the results themselves. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only, or in this case, the announcement of the release date). Although it is an announcement of a future event, the content is directly related to the upcoming earnings report.
2019-05-07 English
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec SE: Release according to Article 41 of the WpHG' and specifically announces the 'Publication of total number of voting rights' following a 'Conditional capital increase'. This type of announcement, which details changes in the total number of shares/voting rights, is a specific corporate action notification. While it relates to capital structure, it is not a general financing update (CAP) or a share repurchase (POS). It is a formal regulatory disclosure regarding the capital structure resulting from a specific measure. Given the options, this fits best under 'Share Issue/Capital Change' (SHA) as it directly reports the resulting total number of voting rights after a capital measure, or potentially 'Regulatory Filings' (RNS) if SHA is too specific for this exact format. However, since it explicitly details a change in the total voting rights following a capital measure, SHA is the most precise fit among the defined categories for capital structure changes.
2019-04-30 English
EVOTEC COMPLETES REPAYMENT OF EUR 140 M ACQUISITION LOAN
Capital/Financing Update Classification · 98% confidence The document is a short news release dated April 18, 2019, announcing that Evotec SE has completed the repayment of a EUR 140M acquisition loan. It highlights strong operational cash flow and mentions previous repayments. This type of announcement, focusing on a specific financial event (debt repayment) that is not a full periodic report (like 10-K or IR), a dividend declaration, or a management change, fits best under 'Capital/Financing Update' (CAP). It is too specific for a general 'Regulatory Filing' (RNS) and does not relate to earnings (ER), dividends (DIV), or share transactions (POS). Since it details a significant financing activity (repayment of debt used for an acquisition), CAP is the most appropriate classification.
2019-04-18 English
Half-yearly financial report 2016
Interim / Quarterly Report Classification · 100% confidence The document is titled 'HALF-YEAR REPORT 2016' and contains detailed financial statements, including an 'Interim Consolidated Statement of Financial Position' and 'Interim Consolidated Income Statement' for the period ending June 30, 2016. It also includes a management report section. Since it is a comprehensive financial report for a period shorter than a full fiscal year (half-year) and contains actual financial data, it fits the definition of an Interim/Quarterly Report (IR). H2 2016
2019-04-16 English
EVOTEC AND INDIVUMED ANNOUNCE STRATEGIC DRUG DISCOVERY COLLABORATION ON PRECISION MEDICINE FOR COLORECTAL CANCER
Environmental & Social Information Classification · 99% confidence The document is a press release dated April 11, 2019, announcing a strategic drug discovery collaboration between Evotec SE and Indivumed GmbH regarding precision medicine for colorectal cancer. It details the terms of the agreement, the scientific rationale, and quotes from management. This type of announcement, which details a significant business development (a partnership/collaboration) but is not a formal financial filing (like 10-K, IR, or ER), typically falls under general corporate news or regulatory announcements. Since it is a specific business development announcement disseminated via a service like DGAP, and it doesn't fit the definitions for M&A (TAR), Financing (CAP), or Director Dealing (DIRS), the most appropriate general category for significant, non-standard corporate news is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements not covered by more specific codes. The document length (under 10,000 characters) and content confirm it is an announcement, not a full report.
2019-04-11 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.